Idiopathic pulmonary fibrosis is the most common type of pulmonary fibrosis that causes ulcers inside the lungs. In addition to Nintedanib, Pirfenidone is currently the only compound approved by the US Food and Drug Administration in 2014 for the treatment of idiopathic pulmonary fibrosis. Meanwhile, in the pharmaceutical industry, drug synthesis is usually done through batch-wise processes, and pirfenidone is currently only produced through batch-wise processes. Hence, this study aims to change the synthesis method of this drug, which is traditionally performed through batch-wise processes, to a continuous flow process. Therefore, a micro-reactor technology can be adopted which offers a...